Stocks and Investing
Stocks and Investing
Mon, October 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joanne Wuensch Maintained (ABT) at Strong Buy with Decreased Target to $122 on, Oct 2nd, 2023
Joanne Wuensch of Citigroup, Maintained "Abbott Laboratories" (ABT) at Strong Buy with Decreased Target from $130 to $122 on, Oct 2nd, 2023.
Joanne has made no other calls on ABT in the last 4 months.
There are 4 other peers that have a rating on ABT. Out of the 4 peers that are also analyzing ABT, 3 agree with Joanne's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Mike Polark of "Wolfe Research" Upgraded from Sell to Hold on, Friday, July 21st, 2023
- Anthony Petrone of "Mizuho" Initiated at Hold with Increased Target to $115 on, Friday, July 21st, 2023
- David Lewis of "Morgan Stanley" Reiterated at Hold and Held Target at $112 on, Friday, July 21st, 2023
This is the rating of the analyst that currently disagrees with Joanne
- Matt Miksic of "Barclays" Maintained at Buy with Increased Target to $132 on, Monday, July 24th, 2023
Contributing Sources